• Equities

Patient conviction: Beyond ‘active share’

Managing high active share portfolios with low turnover fosters an analytical edge.

1 minute read

Miniature workers transport coin to the tallest stack , financial,retail,money saving and business concept

In recent years portions of the fund management industry have been accused of ‘closet indexing’. That is, some funds have been found to be indistinct from the benchmarks they aim to beat yet charge a high fee for this supposedly ‘active’ management of a portfolio. In response, asset management groups have taken to profiling the ‘active share’ of their funds. This is a holdings-based measure of how significantly a portfolio overlaps with its benchmark: owning fewer stocks drives higher active share.  

My ventures are not in one bottom trusted,

Nor to one place, nor is my whole estate,

Upon the fortune of this present year.

Therefore my merchandise makes me not sad.

Active share, however, is not a panacea for performance, as it simply increases the statistical likelihood that portfolio returns will deviate from those of an index without indicating whether that performance is positive or negative. Stockpicking ability is required to increase the chance of a beneficial outcome. 

Yet the uncomfortable truth is that most stocks are losers, failing to beat cash, because the distribution of individual stock returns is non-normal, with very fat tails. One study has found that the entire gain in the US stock market from 1926 to 2015 can be attributable to just the top-performing four percent of listed stocks.1 How, then, to balance this tension: on the one hand, fund managers must create concentrated portfolios with high active share; on the other, the fewer stocks they hold, the less likely they are to own some of the very big winners?

Studies have shown that funds which combine high active share with low turnover have a propensity to outperform.2

We contend that there is something about asking the simple – but not necessarily easy – question, ‘am I willing to own to own a lot of this stock for potentially a very long time?’ which itself becomes a source of analytical advantage. It focuses the investment debate and leads practitioners to play a different game. 

On a month-to-month basis share price returns are dominated by fluctuations in the valuation multiple driven by market sentiment. News-flow and emotions are inherently unpredictable and difficult to anticipate. In contrast, over a multi-year period the valuation multiple becomes overwhelmed by corporate performance measured in changes to returns on capital and cash flow. 

Forecasting future business fundamentals is generally fraught with difficulty. Accordingly, our investment approach seeks out opportunities where islands of relative predictability exist, that enable us to narrow the widening cone of uncertainty that inevitably widens out as one extends time horizons.

Trends like cloud connectivity, electric locks and biopharmaceutical process manufacturers are current examples of themes that have an element of predictability baked in to them. In the case of cloud computing and electric locks, this predictability comes from an inevitable trend being replicated geographically. However, in the case of biopharmaceutical process manufacturers, predictability can be achieved by staking investment further upstream from initial development of drug products – thereby reducing risk. 

Key risks

For further information on the risks and risk profiles of our funds, please refer to the relevant KIID and Prospectus.

The value of an investment and any income from it can go down as well as up and can fluctuate in response to changes in currency exchange rates. Investors may not get back the original amount invested.

Emerging markets risk

The fund invests in emerging markets; these markets may be volatile and carry higher risk than developed markets.

Derivatives risk

The fund uses derivatives; these can be complex and highly volatile. Derivatives may not perform as expected, which means the fund may suffer significant losses.

Illiquid securities risk

Certain assets held in the fund could, by nature, be hard to value or to sell at a desired time or at a price considered to be fair (especially in large quantities), and as a result their prices could be very volatile.

Concentration risk

The fund invests in a small portfolio of securities. Losses from a single investment may be more detrimental to the overall fund performance than if a larger number of investments were made.


  1. Hendrik Bessembinder, 'Do Stocks Outperform Treasury Bills?', 28 May 2018, Journal of Financial Economics (JFE)
  2. Martijn Cremersa and Ankur Pareek, ‘Patient Capital Outperformance: The Investment Skill of High Active Share Managers Who Trade Infrequently’, November 2016; Goldman Sachs, ‘An Rx for Active Management Management: A Behavioral & Market Case Study’, 2017


Global equities in focus

Global Equity Endurance Fund

A strategy that offers a fresh approach to global equity investing.

Find out more

Need more information?

For further information, please contact our investment sales team.

Contact us

Important information


Except where stated as otherwise, the source of all information is Aviva Investors Global Services Limited (AIGSL). Unless stated otherwise any views and opinions are those of Aviva Investors. They should not be viewed as indicating any guarantee of return from an investment managed by Aviva Investors nor as advice of any nature. Information contained herein has been obtained from sources believed to be reliable, but has not been independently verified by Aviva Investors and is not guaranteed to be accurate. Past performance is not a guide to the future. The value of an investment and any income from it may go down as well as up and the investor may not get back the original amount invested. Nothing in this material, including any references to specific securities, assets classes and financial markets is intended to or should be construed as advice or recommendations of any nature. Some data shown are hypothetical or projected and may not come to pass as stated due to changes in market conditions and are not guarantees of future outcomes. This material is not a recommendation to sell or purchase any investment.

The information contained herein is for general guidance only. It is the responsibility of any person or persons in possession of this information to inform themselves of, and to observe, all applicable laws and regulations of any relevant jurisdiction. The information contained herein does not constitute an offer or solicitation to any person in any jurisdiction in which such offer or solicitation is not authorised or to any person to whom it would be unlawful to make such offer or solicitation.

In Europe, this document is issued by Aviva Investors Luxembourg S.A. Registered Office: 2 rue du Fort Bourbon, 1st Floor, 1249 Luxembourg. Supervised by Commission de Surveillance du Secteur Financier. An Aviva company. In the UK, this document is by Aviva Investors Global Services Limited. Registered in England No. 1151805. Registered Office: 80 Fenchurch Street, London, EC3M 4AE. Authorised and regulated by the Financial Conduct Authority. Firm Reference No. 119178. In Switzerland, this document is issued by Aviva Investors Schweiz GmbH.

In Singapore, this material is being circulated by way of an arrangement with Aviva Investors Asia Pte. Limited (AIAPL) for distribution to institutional investors only. Please note that AIAPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIAPL in respect of any matters arising from, or in connection with, this material. AIAPL, a company incorporated under the laws of Singapore with registration number 200813519W, holds a valid Capital Markets Services Licence to carry out fund management activities issued under the Securities and Futures Act (Singapore Statute Cap. 289) and Asian Exempt Financial Adviser for the purposes of the Financial Advisers Act (Singapore Statute Cap.110). Registered Office: 138 Market Street, #05-01 CapitaGreen, Singapore 048946.

In Australia, this material is being circulated by way of an arrangement with Aviva Investors Pacific Pty Ltd (AIPPL) for distribution to wholesale investors only. Please note that AIPPL does not provide any independent research or analysis in the substance or preparation of this material. Recipients of this material are to contact AIPPL in respect of any matters arising from, or in connection with, this material. AIPPL, a company incorporated under the laws of Australia with Australian Business No. 87 153 200 278 and Australian Company No. 153 200 278, holds an Australian Financial Services License (AFSL 411458) issued by the Australian Securities and Investments Commission. Business address: Level 27, 101 Collins Street, Melbourne, VIC 3000, Australia.

The name “Aviva Investors” as used in this material refers to the global organization of affiliated asset management businesses operating under the Aviva Investors name. Each Aviva investors’ affiliate is a subsidiary of Aviva plc, a publicly- traded multi-national financial services company headquartered in the United Kingdom.

Aviva Investors Canada, Inc. (“AIC”) is located in Toronto and is based within the North American region of the global organization of affiliated asset management businesses operating under the Aviva Investors name. AIC is registered with the Ontario Securities Commission as a commodity trading manager, exempt market dealer, portfolio manager and investment fund manager. AIC is also registered as an exempt market dealer and portfolio manager in each province of Canada and may also be registered as an investment fund manager in certain other applicable provinces.

Aviva Investors Americas LLC is a federally registered investment advisor with the U.S. Securities and Exchange Commission. Aviva Investors Americas is also a commodity trading advisor (“CTA”) registered with the Commodity Futures Trading Commission (“CFTC”) and is a member of the National Futures Association (“NFA”). AIA’s Form ADV Part 2A, which provides background information about the firm and its business practices, is available upon written request to: Compliance Department, 225 West Wacker Drive, Suite 2250, Chicago, IL 60606.